ASTRAZENECA PLC

AstraZeneca PLC is a biopharmaceutical enterprise engaged in the discovery, development, and commercialization of therapeutic products. The organization organizes its medical pipeline across primary disease segments, notably Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory and Immunology, and Rare Diseases. Its investigative assets include novel molecular entities such as T-cell engagers, antibody-drug conjugates, CAR-T therapies, radioconjugates, and gene therapies. These treatments are formulated to assist healthcare professionals, clinical investigators, and patients suffering from cancer, autoimmune disorders, organ damage, and serious rare conditions.

The company maintains significant international development ties across the United Kingdom, Sweden, the United States, and China, originating through major corporate mergers and cross-border acquisitions of dedicated biologics and rare disease firms. AstraZeneca PLC is registered and domiciled in the United Kingdom, with corporate registered headquarters established at Cambridge Biomedical Campus in Cambridge, England.

Summary of the business section of Astrazeneca's latest annual report, written by StockData.

“The monthly average number of people, to the nearest hundred, employed by the Group is set out in the table below. In accordance with the Companies Act 2006, this includes part-time employees. … UK 10,600 11,100 10,700”